Curiously, β3-AR expression has been identified in human leukemia [181], where it was involved in myeloid leukemia cell survival under hypoxic conditions to such a quantity that β3-AR could be considered a potential target to reduce chemoresistance, a phenomenon that occurs frequently in leukemic patients [187]. This evidence concerns the gene ADRB3 and myeloid leukemia.